Immunosuppression of experimental autoimmune myasthenia gravis by hydrocortisone and azathioprine
- PMID: 932425
Immunosuppression of experimental autoimmune myasthenia gravis by hydrocortisone and azathioprine
Abstract
Experimental autoimmune myasthenia gravis (EAMG), induced in rabbits by injection of acetylcholine receptor (AChR) from Torpedo californica, was suppressed by appropriate treatment with hydrocortisone or with azathioprine. Administration of hydrocortisone in gradually increasing doses, starting at the time of immunization with the receptor, prevented exacerbation of the disease in the early stages of treatment, as was the case when hydrocortisone was administered in high doses from the beginning. Prolonged administration of the antimetabolite azathioprine (Imuran) prevented the appearance of EAMG, for at least 4 months, in rabbits immunized with AChR. Cell-mediated immunity to AChR was demonstrated to be significantly decreased in such treated animals. The effects of hydrocortisone and azathioprine on EAMG support the view that the disease involves an immunologically cell-mediated mechanism and indicate that the experimental disease can serve as a useful model for chemotherapy of the human disease.
Similar articles
-
Cytophilic antibodies in experimental autoimmune myasthenia gravis.J Immunol. 1977 Jan;118(1):17-20. J Immunol. 1977. PMID: 830746
-
Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.Ann Neurol. 1994 Nov;36(5):704-13. doi: 10.1002/ana.410360504. Ann Neurol. 1994. PMID: 7979216
-
Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits.Eur J Immunol. 1983 Jun;13(6):500-7. doi: 10.1002/eji.1830130613. Eur J Immunol. 1983. PMID: 6861875
-
Animal models of myasthenia gravis.Clin Immunol. 2000 Feb;94(2):75-87. doi: 10.1006/clim.1999.4807. Clin Immunol. 2000. PMID: 10637092 Review.
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
Cited by
-
Immune regulation of experimental myasthenia.J Neurol Neurosurg Psychiatry. 1980 Jul;43(7):634-43. doi: 10.1136/jnnp.43.7.634. J Neurol Neurosurg Psychiatry. 1980. PMID: 7400824 Free PMC article.
-
Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment.J Neurol. 1986 Aug;233(4):221-3. doi: 10.1007/BF00314023. J Neurol. 1986. PMID: 3018180
-
Immunopathology of acetylcholine receptors in myasthenia gravis.Springer Semin Immunopathol. 1982;5(4):389-412. doi: 10.1007/BF01857427. Springer Semin Immunopathol. 1982. PMID: 6761884 Review.
-
Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor.Proc Natl Acad Sci U S A. 1978 Aug;75(8):4006-10. doi: 10.1073/pnas.75.8.4006. Proc Natl Acad Sci U S A. 1978. PMID: 279016 Free PMC article.